We are developing a groundbreaking device platform for autonomous and miniaturized cell therapy production, significantly increasing capacity and reducing costs

Facts about cell therapy

85%

complete remission in r/r ALL patients
after a cell therapy treatment

Source

44%

still cancer free, four years after a single infusion of a cell therapy

Source

3%

of all eligible cancer patients receive a cell therapy

320K

price in EUR of a cell therapy
Kymriah, Germany 2020

Vision

Motivation

Cell Therapy transformed cancer treatment. Sarcura will transform cell therapy manufacturing.

Daniela Buchmayr, MBA
CEO

Sarcura's Solution

Technology

Autonomy

Control intelligence enables the platform to autonomously perform processing and product control for each batch without human interaction

Miniaturization

Semiconductor chip technology and microfluidics enable processing with an unprecedentedly small footprint and cell-level certainty

Modularity

Functional modules allow for individual process designs for various cell types, offering conceptual flexibility

Sarcura secures a €1.7 M grant from FFG

Jul. 2023 / Company

Sarcura appoints a new CTO

Nov. 2022 / Company

Sarcura secures € 7M Seed Plus funding to revolutionize cell therapy manufacturing

Supported by

Partners

"You have to aim high enough to change something. Sarcura is not an usual „evolutionary" startup. Instead, they see the big picture ahead of them and know exactly which steps to take to make it a reality."

Liesbet Lagae
Program Director Life Science Technologies

„Cell therapies have demonstrated enormous potential and the demand is growing. Sarcura's technology has the potential to enable an entire industry to grow and prosper, with benefits to all stakeholders - especially patients.“

Marta Gaia Zanchi
Managing Partner / Nina capital

Powering New Possibles
in Cell Therapy Manufacturing

We are developing a groundbreaking device platform for autonomous and miniaturized cell therapy production, significantly increasing capacity and reducing costs

85%

44%

3%

320K

Cell Therapy transformed cancer treatment. Sarcura will transform cell therapy manufacturing.

Autonomy

Miniaturization

Modularity

Sarcura secures a €1.7 M grant from FFG

Sarcura appoints a new CTO

Sarcura secures € 7M Seed Plus funding to revolutionize cell therapy manufacturing

"You have to aim high enough to change something. Sarcura is not an usual „evolutionary" startup. Instead, they see the big picture ahead of them and know exactly which steps to take to make it a reality."

„Cell therapies have demonstrated enormous potential and the demand is growing. Sarcura's technology has the potential to enable an entire industry to grow and prosper, with benefits to all stakeholders - especially patients.“

Is your area of expertise a fit for Sarcura?
Talk to us!

Powering New Possibles in Cell Therapy Manufacturing

We are developing a groundbreaking device platform for autonomous and miniaturized cell therapy production, significantly increasing capacity and reducing costs

85%

44%

3%

320K

Cell Therapy transformed cancer treatment. Sarcura will transform cell therapy manufacturing.

Autonomy

Miniaturization

Modularity

Sarcura secures a €1.7 M grant from FFG

Sarcura appoints a new CTO

Sarcura secures € 7M Seed Plus funding to revolutionize cell therapy manufacturing

"You have to aim high enough to change something. Sarcura is not an usual „evolutionary" startup. Instead, they see the big picture ahead of them and know exactly which steps to take to make it a reality."

„Cell therapies have demonstrated enormous potential and the demand is growing. Sarcura's technology has the potential to enable an entire industry to grow and prosper, with benefits to all stakeholders - especially patients.“

Is your area of expertise a fit for Sarcura? Talk to us!

Powering New Possibles
in Cell Therapy Manufacturing

Is your area of expertise a fit for Sarcura?
Talk to us!